RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

While investor enthusiasm often focuses on big tech, clinical-stage biotech Recursion Pharmaceuticals (NASDAQ: RXRX) is emerging as a distinctive player in the AI-driven drug discovery space. Founded ...

JDK 25 brings powerful new features to Java and JVM developers. Here are seven new or updated features that could convince you to switch. Java continues its fast and feature-packed release schedule, ...

U.S. prosecutors last week levied criminal hacking charges against 19-year-old U.K. national Thalha Jubair for allegedly being a core member of Scattered Spider, a prolific cybercrime group blamed for ...

at org.mybatis.spring.SqlSessionTemplate$SqlSessionInterceptor.invoke(SqlSessionTemplate.java:441) at com.sun.proxy.$Proxy98.insert(Unknown Source) at org.mybatis ...

Java remains one of the most widely used programming languages in software development, from enterprise apps to Android. If you’re looking to build real skills and prepare for certification, the 2025 ...

The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...